Antipsychotics for patients with pain |
Shin, Sang Wook
(Department of Anesthesia and Pain Medicine, Pusan National University)
Lee, Jin Seong (Department of Psychiatry, Pusan National University) Abdi, Salahadin (Department of Pain Medicine, Division of Anesthesia and Critical Care, The University of Texas MD Anderson Cancer Center) Lee, Su Jung (Department of Anesthesia and Pain Medicine, Pusan National University) Kim, Kyung Hoon (Department of Anesthesia and Pain Medicine, Pusan National University) |
1 | Skogseid IM. Dystonia--new advances in classification, genetics, pathophysiology and treatment. Acta Neurol Scand 2014; 129: 13-9. DOI |
2 | Kurlan R, Rabin M L. P seudoparkinsonism: a review of a common nonparkinsonian hypokinetic movement disorder. Adv Parkinson Dis 2013; 2: 108-12. DOI |
3 | Glazer WM, Morgenstern H, Doucette JT. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J Clin Psychiatry 1993; 54: 133-9. |
4 | Munetz MR, Schulz SC. Screening for tardive dyskinesia. J Clin Psychiatry 1986; 47: 75-7. |
5 | Uhlyar S, Rey JA. Valbenazine (Ingrezza): the first FDAapproved treatment for tardive dyskinesia. P T 2018; 43: 328-31. |
6 | Markowitz JD, Narasimhan M. Delirium and antipsychotics: a systematic review of epidemiology and somatic treatment options. Psychiatry (Edgmont) 2008; 5: 29-36. DOI |
7 | Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002; 47: 27-38. |
8 | Brixner DI, Said Q, Corey-Lisle PK, Tuomari AV, L'italien GJ, Stockdale W, et al. Naturalistic impact of second-generation antipsychotics on weight gain. Ann Pharmacother 2006; 40: 626-32. DOI |
9 | Glazer WM. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry 2000; 61: 16-21. DOI |
10 | Miller DD. Atypical antipsychotics: sleep, sedation, and efficacy. Prim Care Companion J Clin Psychiatry 2004; 6: 3-7. DOI |
11 | Gentile S. Contributing factors to weight gain during longterm treatment with second-generation antipsychotics. A systematic appraisal and clinical implications. Obes Rev 2009; 10: 527-42. DOI |
12 | Roerig JL, Steffen KJ, Mitchell JE. Atypical antipsychoticinduced weight gain: insights into mechanisms of action. CNS Drugs 2011; 25: 1035-59. DOI |
13 | Taylor DM, McAskill R. Atypical antipsychotics and weight gain--a systematic review. Acta Psychiatr Scand 2000; 101: 416-32. DOI |
14 | Cohen D. Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature. Pharmacopsychiatry 2004; 37: 1-11. |
15 | Schwenkreis P, Assion HJ. Atypical antipsychotics and diabetes mellitus. World J Biol Psychiatry 2004; 5: 73-82. DOI |
16 | Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. J Clin Psychiatry 2001; 62: 15-26. |
17 | Leucht S, Samara M, Heres S, Patel MX, Woods SW, Davis JM. Dose equivalents for second-generation antipsychotics: the minimum effective dose method. Schizophr Bull 2014; 40: 314-26. DOI |
18 | Khouzam HR. Psychopharmacology of chronic pain: a focus on antidepressants and atypical antipsychotics. Postgrad Med 2016; 128: 323-30. DOI |
19 | Leucht S, Samara M, Heres S, Patel MX, Furukawa T, Cipriani A, et al. Dose equivalents for second-generation antipsychotic drugs: the classical mean dose method. Schizophr Bull 2015; 41: 1397-402. DOI |
20 | Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003; 64: 663-7. DOI |
21 | Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ 2005; 172: 1703-11. DOI |
22 | Targum SD. Treating psychotic symptoms in elderly patients. Prim Care Companion J Clin Psychiatry 2001; 3: 156-63. DOI |
23 | Leo RJ, Regno PD. Atypical antipsychotic use in the treatment of psychosis in primary care. Prim Care Companion J Clin Psychiatry 2000; 2: 194-204. DOI |
24 | Seidel S, Aigner M, Ossege M, Pernicka E, Wildner B, Sycha T. Antipsychotics for acute and chronic pain in adults. Cochrane Database Syst Rev 2008: CD004844. |
25 | Seidel S, Aigner M, Ossege M, Pernicka E, Wildner B, Sycha T. Antipsychotics for acute and chronic pain in adults. J Pain Symptom Manage 2010; 39: 768-78. DOI |
26 | Ramachandraiah CT, Subramaniam N, Tancer M. The story of antipsychotics: past and present. Indian J Psychiatry 2009; 51: 324-6. DOI |
27 | Worrel JA, Marken PA, Beckman SE, Ruehter VL. Atypical antipsychotic agents: a critical review. Am J Health Syst Pharm 2000; 57: 238-55. DOI |
28 | Gottfries CG, Green L. Flupenthixol decanoate--in treatment of out-patients. Acta Psychiatr Scand Suppl 1974; 255:15-24. DOI |
29 | Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III--the final common pathway. Schizophr Bull 2009; 35: 549-62. DOI |
30 | Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 1081-90. DOI |
31 | Pain terms: a list with definitions and notes on usage. Recommended by the IASP Subcommittee on Taxonomy. Pain 1979; 6: 249. |
32 | Stroup TS, Alves WM, Hamer RM, Lieberman JA. Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations. Nat Rev Drug Discov 2006; 5: 133-46. DOI |
33 | Yang AC, Tsai SJ. New targets for schizophrenia treatment beyond the dopamine hypothesis. Int J Mol Sci 2017; 18:1689. DOI |
34 | Inada T. Evaluation and diagnosis of drug-induced extrapyramidal symptoms: commentary on the DIEPSS and guide to i ts usage. Tokyo, Seiwa Shoten Publishers. 1996. |
35 | Knol W, Keijsers CJ, Jansen PA, van Marum RJ. Systematic evaluation of rating scales for drug-induced parkinsonism and recommendations for future research. J Clin Psychopharmacol 2010; 30: 57-63. DOI |
36 | Chouinard G, Margolese HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res 2005; 76: 247-65. DOI |
37 | Holloman LC, Marder SR. Management of acute extrapyramidal effects induced by antipsychotic drugs. Am J Health Syst Pharm 1997; 54: 2461-77. DOI |
38 | Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VS, et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord 2013; 28: 863-73. DOI |